Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT01151423 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Acquired Thrombotic Thrombocytopenic Purpura

Interventions

BIOLOGICAL: Caplacizumab
BIOLOGICAL: Placebo

Sponsor

Ablynx, a Sanofi company